Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) Sellers Rose Their Shorts By 4.93% As Of Dec 8, 2018

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) Corporate Logo

It was noted an increase on Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE)’s short interest with 4.93%. In December was issued ZYNE’s total 1.78 million short interest by FINRA. Previously was reported up change of 4.93% from 1.70M shares. With Average volume 834,000, ZYNE’s previous position will take 2 days to restore. Zynerba Pharmaceuticals Inc float short is 15.02%.

The stock increased 0.63% or $0.03 during the last trading session, hitting $4.8.Zynerba Pharmaceuticals, Inc. has volume of 116,227 shares. Since December 8, 2017 ZYNE has risen 9.92% and is uptrending. ZYNE underperformed by 5.70% the S&P500.

Zynerba Pharmaceuticals, Inc., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery.The firm is valued at $84.61 million. The Company’s product candidates include ZYN002, which is in Phase II clinical trial for adult patients with refractory epileptic focal seizures and osteoarthritis, as well as pediatric patients with fragile X syndrome; and ZYN001 that is in preclinical stage for the treatment of fibromyalgia and peripheral neuropathic pain.Last it reported negative earnings. The firm was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014.

For more Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) news brought out recently go to: Benzinga.com, Benzinga.com, Seekingalpha.com, Benzinga.com or Globenewswire.com. The titles are as follows: “What Is CBD — And How Can Investors Take Advantage Of It? – Benzinga” brought out on November 15, 2018, “Analyst Upgrades Zynerba (NASDAQ: ZYNE), Encouraged By Prospects For Fragile X Phase 2 Study – Benzinga” on October 02, 2017, “Zynerba: Why I’m Not Buying The High – Seeking Alpha” with a publish date: October 05, 2017, “HC Wainwright Unfazed By Zynerba (NASDAQ:ZYNE) Ending ZYN001: Drug ‘Wasn’t In Our Numbers’ – Benzinga” and the last “Zynerba Pharmaceuticals Announces Twelve Month ZYN002 Data from STAR 2 Study in Patients with Focal Seizures at the 2018 Annual Meeting of the American Academy of Neurology (AAN) – GlobeNewswire” with publication date: April 25, 2018.

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.